Jagsonpal Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹81 Cr +9.5% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
JP

Jagsonpal Pharmaceuticals Ltd

Q4 FY25Pharmaceuticals & Biotechnology

Jagsonpal Pharmaceuticals Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹59Cr
+37.2% YoY
−20.3% QoQ
Net profit
₹7Cr
+75% YoY
−78.1% QoQ
Margin
15%
+9 pp YoY
−6 pp QoQ

Jagsonpal Pharmaceuticals Ltd Q4 FY25 key numbers

Revenue
Growth driven by improved medical rep productivity (currently INR2 to 2.1 lakhs PCPM) with aspiration to increase productivity by 50% over 3-4 years.

As stated in Jagsonpal Pharmaceuticals Ltd's Q4 FY25 earnings call transcript · published 15 Jul 2026. Reported figures, not investment advice.

Price₹237
Market cap₹1.5K Cr
P/E31.8

The short version

Target organic growth: 12% to 15% per year going forward, improving from 8% in FY25. The company aspires to achieve a 15% revenue growth rate internally.

From Jagsonpal Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Target organic growth: 12% to 15% per year going forward, improving from 8% in FY25.
  • Inorganic growth not forecasted due to unpredictability of acquisitions.
  • Growth driven by improved medical rep productivity (currently INR2 to 2.1 lakhs PCPM) with aspiration to increase productivity by 50% over 3-4 years.
  • Sales growth impacted by product mix changes; volumes have been flat due to decline in specific franchises like Dydrogesterone.
  • Launching 4 to 6 new products annually, mainly extensions and some new molecules.

2 more points from Jagsonpal Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Jagsonpal Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Jagsonpal Pharmaceuticals follows an asset-light model with no own manufacturing; all products for India are produced using CMOs.
  • The company has no significant capex plans for building plants or machinery.
  • Investment is primarily in computer infrastructure and office/field force technology.
  • Real capital investment focus is on acquisitions – primarily brand or business acquisitions fitting strategic therapeutic areas.
  • The company remains disciplined on acquisitions, focusing on fair valuations and value addition for shareholders.
  • If suitable acquisition targets are not found, surplus cash will be returned to shareholders instead of spending on overpriced or non-strategic deals.

2 more points from Jagsonpal Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Jagsonpal Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Jagsonpal Pharmaceuticals Ltd Q4 FY25 results — key figures

Jagsonpal Pharmaceuticals Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue5943+37.2%74-20.3%
Operating profit (EBITDA)93+200%16-43.7%
Operating margin15%6%+9 pp21%-6 pp
Profit before tax95+80%39-76.9%
Net profit (PAT)74+75%32-78.1%
EPS (₹)0.990.54+83.3%4.82-79.5%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹81 Cr, net profit ₹13 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Lincoln Pharmaceuticals (Q4 FY25)

    Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Jagsonpal Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Jagsonpal Pharmaceuticals Ltd Q4 FY25 results?

Target organic growth: 12% to 15% per year going forward, improving from 8% in FY25. The company aspires to achieve a 15% revenue growth rate internally.

What is Jagsonpal Pharmaceuticals Ltd share price analysis?

Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.

Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?

Jagsonpal Pharmaceuticals follows an asset-light model with no own manufacturing; all products for India are produced using CMOs.

Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.